Our mission is to provide a new dawn or “eos” for the one in every eight people around the world who are suffering from mental illness.​

Newleos Therapeutics is a clinical-stage biotechnology company co-founded by Longwood Fund and seasoned leaders in CNS drug development. Our pipeline was licensed from Roche and focuses on innovative neuropsychiatric mechanisms of action that aim to reduce side effects and improve outcomes compared to the current standard of care. Our clinical-stage, oral small molecules target GABAA-γ1, V1a, TAAR1 and GABAA-α5, with first- or best-in-class potential in the treatment of general anxiety, social anxiety, substance use disorders, and cognitive impairment.